Core Viewpoint - Jilin Aodong's stock price has shown fluctuations, with a recent decline of 2.04%, while the company has reported a significant increase in net profit year-on-year despite a decrease in revenue [1][2]. Group 1: Stock Performance - As of January 8, Jilin Aodong's stock price was 20.13 yuan per share, with a market capitalization of 24.073 billion yuan [1]. - The stock has increased by 3.07% year-to-date, with a 2.60% rise over the last five trading days and a 4.19% increase over the last 20 days, but has decreased by 1.00% over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, Jilin Aodong reported operating revenue of 1.640 billion yuan, a year-on-year decrease of 14.10%, while net profit attributable to shareholders was 2.260 billion yuan, reflecting an increase of 81.70% [2]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Jilin Aodong was 61,200, a decrease of 7.18% from the previous period, with an average of 19,456 circulating shares per shareholder, an increase of 7.73% [2]. - The company has distributed a total of 4.664 billion yuan in dividends since its A-share listing, with 1.881 billion yuan distributed over the last three years [3]. Group 4: Institutional Holdings - Among the top ten circulating shareholders as of September 30, 2025, the Southern CSI 500 ETF held 13.93 million shares, a decrease of 317,900 shares from the previous period, while the Hong Kong Central Clearing Limited held 11.82 million shares, down by 3.1962 million shares [3].

Core Viewpoint - Jilin Aodong's stock price has experienced fluctuations, with a recent decline of 2.01%, while the company shows a significant increase in net profit year-on-year despite a decrease in revenue [1][2]. Group 1: Stock Performance - As of November 17, Jilin Aodong's stock price is 20.49 CNY per share, with a market capitalization of 24.504 billion CNY [1]. - The stock has increased by 22.11% year-to-date, but has decreased by 4.61% over the last five trading days [1]. - The trading volume on November 17 was 1.01 billion CNY, with a turnover rate of 0.41% [1]. Group 2: Financial Performance - For the period from January to September 2025, Jilin Aodong reported revenue of 1.640 billion CNY, a year-on-year decrease of 14.10% [2]. - The net profit attributable to shareholders for the same period was 2.260 billion CNY, reflecting a year-on-year increase of 81.70% [2]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders is 61,200, a decrease of 7.18% from the previous period [2]. - The average number of circulating shares per shareholder is 19,456, which has increased by 7.73% [2]. - The company has distributed a total of 4.664 billion CNY in dividends since its A-share listing, with 1.881 billion CNY distributed in the last three years [3].

Core Viewpoint - Jilin Aodong's stock price has shown a significant increase this year, with a notable rise in net profit despite a decrease in revenue, indicating potential resilience in its business model and market positioning [1][2]. Financial Performance - As of September 30, 2025, Jilin Aodong reported a revenue of 1.64 billion yuan, a year-on-year decrease of 14.10%, while the net profit attributable to shareholders was 2.26 billion yuan, reflecting a year-on-year increase of 81.70% [2]. - The company's stock price increased by 28.67% year-to-date, with a 0.84% rise over the last five trading days, 6.18% over the last 20 days, and 13.91% over the last 60 days [1]. Shareholder Information - The number of shareholders decreased by 7.18% to 61,200, while the average circulating shares per person increased by 7.73% to 19,456 shares [2]. - The company has distributed a total of 4.664 billion yuan in dividends since its A-share listing, with 1.881 billion yuan distributed in the last three years [3]. Ownership Structure - As of September 30, 2025, the top ten circulating shareholders included Southern CSI 500 ETF, holding 13.93 million shares (a decrease of 317,900 shares), and Hong Kong Central Clearing Limited, holding 11.82 million shares (a decrease of 319,620 shares) [3].

Core Viewpoint - Jilin Aodong's stock price has shown significant growth this year, with a 23.47% increase, and the company is actively involved in various sectors including traditional Chinese medicine and health products [1][2]. Financial Performance - For the first half of 2025, Jilin Aodong reported a revenue of 1.126 billion yuan, a year-on-year decrease of 20.21%, while the net profit attributable to shareholders was 1.282 billion yuan, reflecting a year-on-year increase of 138.44% [2]. - Cumulative cash dividends since the company's A-share listing amount to 4.664 billion yuan, with 1.881 billion yuan distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders for Jilin Aodong was 66,000, a decrease of 1.60% from the previous period, with an average of 18,059 circulating shares per shareholder, an increase of 1.62% [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 4.6149 million shares to 15.0138 million shares, and Southern CSI 500 ETF, which increased its holdings by 1.9148 million shares to 14.2479 million shares [3].

Core Viewpoint - Jilin Aodong's stock price has shown significant growth this year, with a 20.41% increase, and the company is actively involved in various sectors including traditional Chinese medicine and health products [1][2]. Financial Performance - For the first half of 2025, Jilin Aodong reported a revenue of 1.126 billion yuan, a year-on-year decrease of 20.21%, while the net profit attributable to shareholders was 1.282 billion yuan, reflecting a year-on-year increase of 138.44% [2]. - Cumulative cash dividends since the company's A-share listing amount to 4.43 billion yuan, with 1.647 billion yuan distributed over the past three years [3]. Stock Market Activity - As of October 9, Jilin Aodong's stock price was 20.44 yuan per share, with a market capitalization of 24.444 billion yuan. The stock has seen a trading volume of 292 million yuan and a turnover rate of 1.23% [1]. - The stock has experienced a net inflow of 8.2328 million yuan from main funds, with significant buying and selling activity noted [1]. Shareholder Structure - As of June 30, 2025, the number of shareholders decreased to 66,000, with an average of 18,059 circulating shares per person, an increase of 1.62% [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited and Southern CSI 500 ETF, with notable increases in their holdings [3].

Group 1 - Jilin Aodong Pharmaceutical Group Co., Ltd. experienced a stock price increase of 5.23%, reaching 20.12 CNY per share, with a trading volume of 419 million CNY and a turnover rate of 1.80%, resulting in a total market capitalization of 24.061 billion CNY [1] - The company, established on March 20, 1993, and listed on October 28, 1996, specializes in the research, development, manufacturing, and sales of traditional Chinese medicine and biochemical drugs, while also expanding into health foods, food, breeding, and planting sectors [1] - The revenue composition of Jilin Aodong includes traditional Chinese medicine at 60.90%, wholesale and retail of chain pharmacies at 16.59%, chemical drugs at 12.73%, food at 7.39%, and other products at 1.76% [1] Group 2 - Southern Fund's Southern CSI 500 ETF (510500) is among the top ten circulating shareholders of Jilin Aodong, having increased its holdings by 1.9148 million shares in the second quarter, totaling 14.2479 million shares, which represents 1.2% of the circulating shares [2] - The Southern CSI 500 ETF (510500) has a current scale of 113.438 billion CNY, with a year-to-date return of 28.25%, ranking 1796 out of 4221 in its category, and a one-year return of 48.6%, ranking 1589 out of 3836 [2] Group 3 - The Southern CSI 500 Enhanced Strategy ETF (560100) holds 29,800 shares of Jilin Aodong, accounting for 0.63% of the fund's net value, making it the ninth-largest holding [4] - The Southern CSI 500 Enhanced Strategy ETF (560100) has a current scale of 80.4132 million CNY, with a year-to-date return of 27.63%, ranking 1852 out of 4221 in its category, and a one-year return of 45.75%, ranking 1710 out of 3836 [4]

Core Viewpoint - Jilin Aodong's stock performance shows a mixed trend with a year-to-date increase of 13.98% and a recent decline over the past 20 days, indicating potential volatility in the market [1][2]. Group 1: Stock Performance - As of September 11, Jilin Aodong's stock price increased by 2.00% to 19.35 CNY per share, with a trading volume of 1.94 billion CNY and a turnover rate of 0.85%, resulting in a total market capitalization of 231.41 billion CNY [1]. - The stock has seen a year-to-date increase of 13.98%, a 2.60% rise over the last five trading days, a 1.38% decline over the last 20 days, and a 21.35% increase over the last 60 days [1]. Group 2: Financial Performance - For the first half of 2025, Jilin Aodong reported a revenue of 1.126 billion CNY, a year-on-year decrease of 20.21%, while the net profit attributable to shareholders was 1.282 billion CNY, reflecting a significant year-on-year increase of 138.44% [2]. Group 3: Shareholder and Dividend Information - Since its A-share listing, Jilin Aodong has distributed a total of 4.43 billion CNY in dividends, with 1.647 billion CNY distributed over the past three years [3]. - As of June 30, 2025, the number of shareholders decreased to 66,000, while the average circulating shares per person increased by 1.62% to 18,059 shares [2][3]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 15.0138 million shares, an increase of 4.6149 million shares from the previous period [3].

Group 1 - The latest stock price of Jilin Aodong is 20.55 yuan, an increase of 0.61 yuan from the previous trading day, with a trading volume of 6.22 billion yuan [1] - Jilin Aodong is primarily engaged in the research, development, manufacturing, and sales of traditional Chinese medicine and biochemical drugs, covering various therapeutic areas including cardiovascular, digestive system, and anti-tumor treatments [1] - On August 22, Jilin Aodong announced that it has returned all 300 million yuan of temporarily idle raised funds to the special account for raised funds [1] Group 2 - On the same day, the net inflow of main funds into Jilin Aodong was 33.96 million yuan, while the net outflow over the past five days was 71.64 million yuan [2]